4.58
Avita Medical Inc stock is traded at $4.58, with a volume of 183.85K.
It is up +2.23% in the last 24 hours and down -1.93% over the past month.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
See More
Previous Close:
$4.48
Open:
$4.61
24h Volume:
183.85K
Relative Volume:
0.76
Market Cap:
$140.96M
Revenue:
$71.61M
Net Income/Loss:
$-48.59M
P/E Ratio:
-2.6156
EPS:
-1.751
Net Cash Flow:
$-32.88M
1W Performance:
+0.44%
1M Performance:
-1.93%
6M Performance:
+20.84%
1Y Performance:
-28.44%
Avita Medical Inc Stock (RCEL) Company Profile
Name
Avita Medical Inc
Sector
Industry
Phone
661-568-1317
Address
28159 AVENUE STANFORD, VALENCIA, CA
Compare RCEL vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
RCEL
Avita Medical Inc
|
4.58 | 137.88M | 71.61M | -48.59M | -32.88M | -1.751 |
|
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Avita Medical Inc Stock (RCEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Initiated | Northland Capital | Outperform |
| Nov-20-25 | Upgrade | BTIG Research | Sell → Neutral |
| Aug-08-25 | Downgrade | BTIG Research | Neutral → Sell |
| Dec-24-24 | Initiated | D. Boral Capital | Buy |
| Apr-11-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-27-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-21 | Initiated | Piper Sandler | Overweight |
| Aug-27-20 | Initiated | BofA Securities | Buy |
| Apr-21-20 | Initiated | Oppenheimer | Outperform |
| Mar-03-20 | Initiated | BTIG Research | Buy |
View All
Avita Medical Inc Stock (RCEL) Latest News
Avita Medical Stock Price Forecast. Should You Buy RCEL? - StockInvest.us
Avita Medical Q1 earnings call highlights - MSN
Morgans says these ASX shares could rise 12% to 20% - MSN
Insider Buying: David O'Toole Acquires Shares of AVITA Medical I - GuruFocus
AVITA Medical (RCEL) CFO adds 2,000 shares in open-market buy - Stock Titan
AVITA Medical (RCEL) CFO adds 2,000 shares in open-market purchase - Stock Titan
AVITA Medical to Host Investor Webinar Briefing - Investing News Network
AVITA Medical to Host Investor Webinar Briefing | Associated Press | syndication news - Enidnews.com
Two AVITA Medical investor Q&As with CEO Cary Vance on May 20–21 - Stock Titan
AVITA Medical, Inc. (NASDAQ:RCEL) Q1 2026 Earnings Call Transcript - Insider Monkey
AVITA Medical Q1 2026 earnings preview - MSN
RCEL Upgraded by Lake Street -- Price Target Raised to $6.00 - GuruFocus
Avita Medical Raised to Buy From Hold by Lake Street - Moomoo
Avita Medical, Inc. Stock 12‑Month Price Target Raised to $6.99, Implies 60% Upside - TradingView
Avita (RCEL) Q1 2026 Earnings Call Transcript - The Globe and Mail
TD Cowen Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $5.5 - Moomoo
AVITA Medical, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Avita reaffirms $80M-$85M 2026 revenue guidance as RECELL reimbursement normalizes and Cohealyx data targets faster graft readiness - MSN
Lake Street upgrades AVITA Medical (RCEL) - MSN
RCEL Reports Q1 Revenue Below Expectations - GuruFocus
RCEL Revenue Forecast for FY26 Indicates Strong Growth Potential - GuruFocus
Is AVITA Medical (RCEL) a Value Trap Despite Q1 2026 Revenue Bea - GuruFocus
AVITA Medical Inc (AVHHL) Q1 2026 Earnings Call Highlights: Reve - GuruFocus
Avita Medical Posts Narrower Q1 Loss, Higher Revenue; Reaffirms Full-Year 2026 Outlook - Moomoo
AVITA Medical's (ASX:AVH) First Quarter 2026 Results and Strategic Reset Explained - Kalkine
Avita Medical Q1 Earnings Call Highlights - MarketBeat
AVITA Medical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RCEL: Revenue rose 4% year-over-year to $19.3M, with improved margins and reaffirmed guidance - TradingView
Avita Medical earnings missed by $0.06, revenue topped estimates - Investing.com Canada
AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
AVITA Medical Reports First Quarter 2026 Financial Results - Investing News Network
Avita Medical stock (US0301011039): Q1 2026 results and revenue details - AD HOC NEWS
RCEL: Q1 2026 delivered revenue growth, improved margins, and strong clinical momentum for new products - TradingView
Q1 2026 AVITA Medical Inc Earnings Call Transcript - GuruFocus
AVITA Medical (RCEL) posts Q1 2026 loss, adds new credit line and BARDA deal - Stock Titan
AVITA Medical (RCEL) Q1 2026 revenue rises 4% as losses narrow and 2026 outlook held - Stock Titan
AVITA Medical, Inc. Reaffirms Earnings Guidance for the Full Year 2026 - marketscreener.com
AVITA Medical Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Avita Medical stock (US0301011039): Shares surged 7.75% in July 2025 - AD HOC NEWS
TradingKey - TradingKey
Avita Medical Inc. (NASDAQ:RCEL) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
AVITA Medical Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
RCEL Stock Price, Quote & Chart | AVITA MEDICAL INC (NASDAQ:RCEL) - ChartMill
Avita Medical (RCEL) Expected to Announce Earnings on Thursday - MarketBeat
AVITA Medical appoints Cary Vance as permanent CEO - MSN
AVITA Medical Appoints Cary Vance as Permanent CEO and Jan Stern Reed as Board Chair to Drive Growth in Acute Wound Care Solutions - Minichart
Avita Medical Names Cary Vance Permanent CEO, Reshapes Board - The Globe and Mail
Avita Medical (NASDAQ:RCEL) Stock Rating Lowered by Wall Street Zen - MarketBeat
AVITA Medical wins BARDA contract worth up to $25.5M - MSN
Cary Vance becomes AVITA Medical (NASDAQ: RCEL) CEO as Board elevates Jan Stern Reed to Chair - Stock Titan
Avita Medical Appoints CEO, Chair - Moomoo
Avita Medical Inc Stock (RCEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):